Original language | English (US) |
---|---|
Pages (from-to) | 394-419 |
Number of pages | 26 |
Journal | Hepatology |
Volume | 69 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2019 |
ASJC Scopus subject areas
- Hepatology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Hepatology, Vol. 69, No. 1, 01.2019, p. 394-419.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Primary Biliary Cholangitis
T2 - 2018 Practice Guidance from the American Association for the Study of Liver Diseases
AU - Lindor, Keith
AU - Bowlus, Christopher L.
AU - Boyer, James
AU - Levy, Cynthia
AU - Mayo, Marlyn
N1 - Funding Information: Received May 30, 2018; accepted May 30, 2018. The funding for the development of this Practice Guidance was provided by the American Association for the Study of Liver Diseases. This practice guidance was approved by the American Association for the Study of Liver Diseases on April 26, 2018. © 2018 by the American Association for the Study of Liver Diseases. View this article online at wileyonlinelibrary.com. DOI 10.1002/hep.30145 Potential conflict of interest: Dr. Mayo received grants from Intercept, CymaBay, Novartis, Target, Genfit, Mallinckrodt, and GlaxoSmithKline. Dr. Levy consults for Target and Cara. She received grants from Gilead, Intercept, Tobira, NGM, Shire, HighTide, Durect, Novartis, CymaBay, GlaxoSmithKline, Enanta, Genkyotek, and Genfit. She received royalties from Uptodate. Dr. Bowlus consults and received grants from Intercept, GlaxoSmithKline, and Bristol-Myers Squibb. He consults for Conatus, Patara, and Eli Lilly. He received grants from Gilead, CymaBay, Takeda, NGM, Merck, Target, Genkyotek, Allergan, JKB, and Taiwan. Funding Information: The funding for the development of this Practice Guidance was provided by the American Association for the Study of Liver Diseases. This practice guidance was approved by the American Association for the Study of Liver Diseases on April 26, 2018. This updated guidance was produced in collaboration with the AASLD Practice Guidelines Committee, which approved the scope of the guidance and provided peer review. Members of the AASLD Practice Guidelines Committee include George Ioannou, M.D., F.A.A.S.L.D. (Chair), Alfred Sidney Barritt IV, M.D., M.S.C.R., James R. Burton, Jr., M.D., Udeme Ekong, M.D., Ruben Hernaez, M.D., M.P.H., Ph.D., Whitney E. Jackson, M.D., Patricia D. Jones, M.D., M.S.C.R., Patrick S. Kamath, M.D., David G. Koch, M.D., Lopa Mishra, M.D., M.S.C.R., (Board Liaison), David J. Reich, M.D., F.A.C.S., Barry Schlansky, M.D., M.P.H., Amit G. Singal, M.D., M.S. (Vice-Chair), James R. Spivey, M.D., and Elizabeth C. Verna, M.D., M.S.
PY - 2019/1
Y1 - 2019/1
UR - http://www.scopus.com/inward/record.url?scp=85056159111&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056159111&partnerID=8YFLogxK
U2 - 10.1002/hep.30145
DO - 10.1002/hep.30145
M3 - Article
C2 - 30070375
AN - SCOPUS:85056159111
SN - 0270-9139
VL - 69
SP - 394
EP - 419
JO - Hepatology
JF - Hepatology
IS - 1
ER -